Industry Calls For EU Action Against French Off-Label Law
This article was originally published in Scrip
The European pharmaceutical industry has filed a second complaint with the European Commission against national legislation allowing the off-label use of cheaper medicines where approved alternatives exist, for purely financial reasons.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?